Colinz Laboratories Ltd

₹ 44.6 -0.11%
27 Jan - close price
colinz.com BSE: 531210
About

Established in 1986, Colinz Laboratories is Limited is engaged in the manufacturing of Pharmaceutical Formulations like
Allopathic, Ayurvedic and Nutraceuticals in dosage forms of Tablets, Capsules, Ointments, Injectables, Syrups, etc. The company has certain specialized products for Gynecology, cardiology, gastroenterology etc.

Key Points

Product Portfolio:[1]
The company is manufacturing and developing a number of products for various therapeutic segments like:
a) Allopathy:[2]
The company manufactures various Oncology products like Imatinib, Erlotinib, Letrozole, etc. Anti-retroviral like Lopinavir, Indinavir, Ritonavir, etc. and also products belonging to therapeutic segments like Antibiotic; Anti pyretic Anti- Fungal, Anti-malarial, Anti-viral, etc.
b) Ayurvedics:[3]
The company manufactures many Ayurvedic products like Anti-diarrhoeals, Anti-pyretics, Anti-inflammatories, Anti-spasmodics, Cough Syrups, Apetite Stimulating Agents, Memory Boosters, Anti-piles, Antacids, Liver Tonic, etc.
c) Nutraceuticals:[4]
Major products manufactured in the Nutraceutical category are Spirulina Tabs /caps, Spirulina With Vitamins & Minerals, Omega 3 Fatty Acids Caps in Soft gel, Cod-liver Oil With Vitamin Caps in Soft Gel, Collagen, Glucosamine & Chondroitin Tabs, Amino acids tabs/caps, etc.

Website BSE
  • Market Cap ₹ 20.4 Cr.
  • Current Price ₹ 44.6
  • High / Low ₹ 61.2 / 23.5
  • Stock P/E 52.2
  • Book Value ₹ 19.7
  • Dividend Yield 0.00 %
  • ROCE 6.80 %
  • ROE 4.54 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company's working capital requirements have reduced from 63.7 days to 35.1 days

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -2.84% over past five years.
  • Company has a low return on equity of 3.18% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
1.99 1.93 1.65 1.42 1.61 1.50 1.64 1.85 1.95 1.59 1.58 1.84 1.92
1.91 1.85 1.63 1.32 1.53 1.41 1.58 1.71 1.77 1.44 1.47 1.69 1.76
Operating Profit 0.08 0.08 0.02 0.10 0.08 0.09 0.06 0.14 0.18 0.15 0.11 0.15 0.16
OPM % 4.02% 4.15% 1.21% 7.04% 4.97% 6.00% 3.66% 7.57% 9.23% 9.43% 6.96% 8.15% 8.33%
0.03 0.03 0.05 0.03 0.06 0.03 0.07 0.04 0.03 0.03 0.07 0.04 0.05
Interest 0.01 0.01 0.01 0.02 0.01 0.03 0.02 0.02 0.02 0.02 0.01 0.01 0.01
Depreciation 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.03 0.03
Profit before tax 0.05 0.05 0.01 0.06 0.08 0.04 0.06 0.11 0.14 0.11 0.12 0.15 0.17
Tax % 20.00% 20.00% 200.00% 16.67% 25.00% 25.00% 0.00% 27.27% 28.57% 18.18% 41.67% 20.00% 29.41%
Net Profit 0.04 0.05 -0.01 0.05 0.06 0.03 0.06 0.08 0.10 0.09 0.07 0.11 0.12
EPS in Rs 0.09 0.11 -0.02 0.11 0.13 0.07 0.13 0.18 0.22 0.20 0.15 0.24 0.26
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
5.70 6.61 7.18 7.41 7.88 8.10 8.05 7.83 7.59 7.53 6.16 6.97 6.93
5.24 6.10 6.64 7.07 7.42 7.65 7.64 7.48 7.24 7.22 5.82 6.38 6.36
Operating Profit 0.46 0.51 0.54 0.34 0.46 0.45 0.41 0.35 0.35 0.31 0.34 0.59 0.57
OPM % 8.07% 7.72% 7.52% 4.59% 5.84% 5.56% 5.09% 4.47% 4.61% 4.12% 5.52% 8.46% 8.23%
0.03 0.03 0.08 0.13 0.10 0.10 0.09 0.10 0.12 0.13 0.19 0.17 0.19
Interest 0.16 0.19 0.20 0.08 0.12 0.12 0.12 0.08 0.10 0.07 0.09 0.08 0.05
Depreciation 0.26 0.26 0.26 0.26 0.30 0.28 0.27 0.22 0.22 0.19 0.19 0.20 0.16
Profit before tax 0.07 0.09 0.16 0.13 0.14 0.15 0.11 0.15 0.15 0.18 0.25 0.48 0.55
Tax % 0.00% -22.22% 50.00% 46.15% 35.71% 40.00% -27.27% -53.33% 26.67% 27.78% 16.00% 29.17%
Net Profit 0.07 0.11 0.08 0.07 0.10 0.09 0.14 0.23 0.12 0.13 0.21 0.34 0.39
EPS in Rs 0.15 0.24 0.18 0.15 0.22 0.20 0.31 0.50 0.26 0.28 0.46 0.74 0.85
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: 1%
5 Years: -3%
3 Years: -3%
TTM: 0%
Compounded Profit Growth
10 Years: 11%
5 Years: 19%
3 Years: 42%
TTM: 44%
Stock Price CAGR
10 Years: 20%
5 Years: 18%
3 Years: 64%
1 Year: 39%
Return on Equity
10 Years: 2%
5 Years: 3%
3 Years: 3%
Last Year: 5%

Balance Sheet

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
3.54 3.54 3.54 3.54 3.54 3.54 3.54 3.54 3.54 3.54 3.55 3.55 2.52
Reserves 2.48 2.64 2.71 2.78 2.62 2.71 2.98 3.21 3.30 3.29 3.75 4.14 5.44
2.85 2.39 2.26 1.88 2.53 1.80 0.76 0.42 0.68 0.38 0.99 0.48 0.57
1.32 1.64 1.35 1.79 1.97 1.70 2.40 2.42 1.65 1.60 1.81 1.76 2.14
Total Liabilities 10.19 10.21 9.86 9.99 10.66 9.75 9.68 9.59 9.17 8.81 10.10 9.93 10.67
4.41 4.24 3.98 3.72 3.16 2.88 2.63 2.41 2.21 2.06 2.03 1.86 1.77
CWIP 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Investments 0.32 0.32 0.32 0.32 0.29 0.29 0.41 0.53 0.50 0.36 0.61 0.67 0.71
5.46 5.65 5.56 5.95 7.21 6.58 6.64 6.65 6.46 6.39 7.46 7.40 8.19
Total Assets 10.19 10.21 9.86 9.99 10.66 9.75 9.68 9.59 9.17 8.81 10.10 9.93 10.67

Cash Flows

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
0.79 0.30 0.15 0.64 0.09 0.58 0.06 0.34 0.12 0.58 2.16 0.47
-0.01 -0.09 0.00 0.00 0.03 0.00 -0.01 -0.11 -0.01 -0.04 -0.16 -0.03
-0.26 -0.45 -0.14 -0.37 0.45 -0.73 -0.03 0.01 0.02 0.06 0.08 0.09
Net Cash Flow 0.52 -0.24 0.01 0.27 0.57 -0.16 0.02 0.24 0.12 0.60 2.07 0.52

Ratios

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 58.91 59.64 64.56 65.51 62.53 60.83 66.65 78.31 80.79 72.22 77.03 63.36
Inventory Days 318.33 290.09 237.38 188.53 288.96 232.18 267.25 266.31 246.80 225.13 208.33 147.59
Days Payable 110.00 125.30 51.05 93.17 116.24 60.66 55.68 91.93 44.16 49.29 90.00 76.17
Cash Conversion Cycle 267.25 224.43 250.89 160.87 235.25 232.35 278.23 252.70 283.42 248.06 195.36 134.78
Working Capital Days 123.59 108.78 113.87 89.65 110.24 100.04 105.65 92.30 122.15 97.43 58.66 35.09
ROCE % 2.46% 3.33% 4.22% 2.51% 3.20% 3.23% 3.00% 3.18% 3.40% 3.39% 4.39% 6.80%

Shareholding Pattern

Numbers in percentages

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
36.42 36.42 36.42 36.42 36.42 36.42 36.41 36.41 36.38 66.01 65.93 66.00
0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00
0.07 0.07 0.07 0.07 0.07 0.07 0.00 0.07 0.07 0.12 0.12 0.12
63.51 63.51 63.51 63.51 63.51 63.51 63.52 63.52 63.56 33.88 33.95 33.89

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports